poisar

Stocks · News reference

Trinity Biotech Enters Collaboration With Intradermal Drug Delivery Platform Maker Latch Medical

Benzinga Newsdesk

The collaboration is intended to combine data streams from Trinity Biotech's CGM+ wearable biosensor platform with Latch Medical's advanced drug delivery technologies to evaluate the development of precision

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

TRIB
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Trinity Biotech Plc

    Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update

    Trinity Biotech announced continued execution of its transformation strategy, including commercial leadership strengthening in Europe, rollout of upgraded HbA1c column technology, and expansion of its PrePsia™ patent portfolio to nine patents. However, the company received a Nasdaq delisting notice after failing to maintain the $15 million minimum market value of publicly held shares requirement by the August 18, 2026 deadline. The company intends to request a hearing before a Nasdaq panel and is pursuing strategic initiatives to regain compliance.

    TRIB